Navigation Links
Pulmonary fibrosis inhibited by pentraxin-2/SAP in research study
Date:2/10/2011

MALVERN, PA February 10, 2011 Promedior, Inc., a clinical stage biotechnology company developing novel therapies to treat fibrotic and inflammatory diseases, announced today the publication of collaborative research in the International Journal of Biochemistry and Cell Biology entitled, "TGF-beta driven lung fibrosis is macrophage dependent and blocked by Serum amyloid P." The research showed that human Pentraxin-2 (PTX-2), also called human Serum amyloid P (SAP), potently inhibits all undesirable pro-fibrotic pathologies driven by TGFβ1 and represents a novel therapeutic approach for the treatment of diseases that involve lung fibrosis, including idiopathic pulmonary fibrosis (IPF). This research validates that PTX-2/SAP can have therapeutic effects even in conditions driven by TGFβ1 growth factor, and builds on the body of research showing the unique role of PTX-2/SAP in activating the body's natural ability to resolve tissue damage in disease processes that cause fibrosis and inflammation.

In this study, researchers examined the effects of PTX-2/SAP in the lung specific TGFβ1 transgenic mouse model, since many of the pathogenic mechanisms observed in lung fibrosis can be stimulated by the growth factor TGFβ1. Highlights of the results from this study validating the potential therapeutic effects of PTX-2/SAP in pulmonary fibrosis included:

  • PTX-2/SAP inhibited all of the pathologies driven by TGFβ1 including apoptosis, airway inflammation, pulmonary fibrocyte and M2 macrophage accumulation and collagen deposition, without affecting the levels of TGFβ1 in the lung;

  • An abbreviated therapeutic dose schedule was equally efficacious and demonstrated a sustained durability of effect following cessation of drug dosing, suggesting that intermittent dosing may be feasible in human patients;

  • PTX-2/SAP levels were reduced in the serum of IPF patients when compared to clos
    '/>"/>

Contact: Kathryn Morris
kathryn@theyatesnetwork.com
845-635-9828
Yates Public Relations
Source:Eurekalert

Page: 1 2 3

Related biology news :

1. A possible role for Smurf1 in pulmonary arterial hypertension
2. Test could predict which idiopathic pulmonary fibrosis patients will become severely ill
3. New potential to treat chronic obstructive pulmonary disease
4. Endothelin drugs benefit those with pulmonary hypertension
5. Pitt team first to profile genes in acutely ill idiopathic pulmonary fibrosis patients
6. Pulmonary hypertension in children may result from reduced activity of gene regulator
7. Gene with probable role in human susceptibility to pulmonary tuberculosis identified
8. Breakthrough on cystic fibrosis 1 step closer as new research alliance formed
9. 1 step closer to a drug treatment for cystic fibrosis, MU professor says
10. Pitt researchers discover big role for microRNA in lethal lung fibrosis
11. Drug may treat cystic fibrosis, other diseases caused by nonsense mutations, UAB researcher says
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/22/2015)... , Jan. 13, 2015  Today, FreeWavz ( www.FreeWavz.com ... its crowdfunding campaign on Fundable, https://www.fundable.com/freewavz . ... of production capacity to meet customer demand. ... - http://photos.prnewswire.com/prnh/20150113/168790 Invented ...
(Date:1/22/2015)... Jan. 20, 2015 NXT-ID, Inc. (NASDAQ: NXTD and ... reports on the recent success of the Wocket™ smart wallet at CES ... smart wallet was named as one of the "11 Hot Products at ... Products Launched At CES So Far" by Newseveryday.com and "The top 10 ...
(Date:1/22/2015)... and Markets ( http://www.researchandmarkets.com/research/wxdglm/global_wearable ) has ... Technologies Market and Applications, Opportunities, Industry Analysis, Segmentation, ... report to their offering. , ... be worn on the user,s body and have ...
Breaking Biology News(10 mins):FreeWavz Launches on Fundable to Drive Speed-to-Market in 2015 2CES Response for NXT-ID's Wocket Smart Wallet Kicks Off 2015 2CES Response for NXT-ID's Wocket Smart Wallet Kicks Off 2015 3Global Wearable Technologies Market and Applications, Opportunities, Industry Analysis, Segmentation, Size, Growth, Share, Overview, Trends and Forecast 2014-2020 2
... ALEXANDRIA, Va., Dec. 9 First Coast Service ... industry leader in Medicare reimbursement solutions, to support ... Centers for Medicare & Medicaid Services (CMS).Under this ... Jan. 1, 2009 between health care providers and ...
... international research team led by Tim Nilsen, Ph.D., a ... the School of Medicine,s Center for RNA Molecular Biology, ... process by which single genes produce different proteins in ... more than half of genetic diseases that are caused ...
... an initiating molecular mechanism in sporadic Alzheimer,s disease ... the December 26th issue of the journal ... damaging amyloid β (Aβ) plaques within the AD ... preventative and disease-modifying therapies for AD, especially those ...
Cached Biology News:FCSO Selects Burgess as Exclusive Pricing Solution for New Medicare Contract 2Case Western Reserve finds mechanism underlying alt. splicing of premessenger RNA into messenger RNA 2Case Western Reserve finds mechanism underlying alt. splicing of premessenger RNA into messenger RNA 3Impaired energy metabolism linked with initiation of plaques in Alzheimer's brain 2
(Date:12/24/2014)... Md. , Dec. 24, 2014  United Therapeutics Corporation ... Inc. (NYSE: MDT ) has submitted a ... Administration (FDA) for the use of Medtronic,s SynchroMed ® ... developed catheter) for use with United Therapeutics, Remodulin ® ...
(Date:12/24/2014)... 24, 2014  Vermillion, Inc. (Nasdaq:   VRML), a ... today that the Company closed its previously announced ... Jack W. Schuler , Birchview Fund LLC ... million, before offering expenses.  The proceeds will be ...
(Date:12/24/2014)... “Preparative & Process Chromatography Market by Instrument ... Buffers, Valves, Guages, Seals), Accessories, Services, End User ... 2019” provides a detailed overview of the major ... strategies impacting the preparative and process chromatography market ...
(Date:12/24/2014)... MA (PRWEB) December 23, 2014 Earlier this ... L. Sherley, director of the Adult Stem Cell Technology Center, ... and under appreciated unique property of adult tissue stem cells. ... in the Past, Important for the Future,” embodied the essence ...
Breaking Biology Technology:United Therapeutics Announces Submission Of Pre-Market Approval Application For Implantable Drug Infusion System To Deliver Remodulin 2United Therapeutics Announces Submission Of Pre-Market Approval Application For Implantable Drug Infusion System To Deliver Remodulin 3United Therapeutics Announces Submission Of Pre-Market Approval Application For Implantable Drug Infusion System To Deliver Remodulin 4Vermillion Announces Closing of Equity Financing 2Vermillion Announces Closing of Equity Financing 3Preparative and Process Chromatography Market is expected to reach $9 billion by 2019 - New Report by Marketsandmarkets 2Preparative and Process Chromatography Market is expected to reach $9 billion by 2019 - New Report by Marketsandmarkets 3Preparative and Process Chromatography Market is expected to reach $9 billion by 2019 - New Report by Marketsandmarkets 4Adult Stem Cell Technology Center, LLC’s Director Sherley's Address on What’s Holding Back Regenerative Medicine Featured on Omics Group Website 2Adult Stem Cell Technology Center, LLC’s Director Sherley's Address on What’s Holding Back Regenerative Medicine Featured on Omics Group Website 3Adult Stem Cell Technology Center, LLC’s Director Sherley's Address on What’s Holding Back Regenerative Medicine Featured on Omics Group Website 4
... Proteon Therapeutics, Inc., announced today that it has successfully ... by MPM Capital on behalf of the MPM Bio ... the initiation of a Phase 1/2 human clinical study ... stage renal disease undergoing surgery for arteriovenous fistula (AVF) ...
... Arney to Vice President and Helena Rojas to Director of Global ... ... 5, 2009 -- CSOFT International Ltd., a leading provider of multilingual ... the promotion of Matt Arney to Vice President of Global Business ...
... /PRNewswire-FirstCall/ - Oncolytics Biotech Inc. (TSX:ONC, NASDAQ: ONCY ... results for the year ended December 31, 2008. , ... REOLYSIN(R)," said Dr. Brad Thompson, President and CEO of ... supported by interim results reported in our US and ...
Cached Biology Technology:Proteon Therapeutics Completes $38M Equity Financing; Initiates Phase 1/2 Clinical Study of PRT-201 in Hemodialysis Patients and Signs Option Agreement With Major Pharmaceutical Company 2Localization and Translation Leader CSOFT International Ltd. Recognizes Efforts of Two Key Members of its Business Development Team 2Localization and Translation Leader CSOFT International Ltd. Recognizes Efforts of Two Key Members of its Business Development Team 3Oncolytics Biotech(R) Inc. Reports Highlights and Financial Results for 2008 2Oncolytics Biotech(R) Inc. Reports Highlights and Financial Results for 2008 3Oncolytics Biotech(R) Inc. Reports Highlights and Financial Results for 2008 4Oncolytics Biotech(R) Inc. Reports Highlights and Financial Results for 2008 5Oncolytics Biotech(R) Inc. Reports Highlights and Financial Results for 2008 6Oncolytics Biotech(R) Inc. Reports Highlights and Financial Results for 2008 7Oncolytics Biotech(R) Inc. Reports Highlights and Financial Results for 2008 8Oncolytics Biotech(R) Inc. Reports Highlights and Financial Results for 2008 9
... trap mass spectrometer enables high-throughput solutions for ... linear ion trap mass spectrometer is designed ... the fast cycle time and increased sensitivity ... an attractive price. The combination of ...
... The S&S Custom Processing Service enables scientists who ... and data analysis software to have their biological ... 16 analytes. Its as easy as 1-2-3 ... quantified in your samples from the S&S antibody ...
... 1) Persistent Analysis Environment 2) ... Histograms, etc. 3) Software Compensation 4) ... Advanced Kinetics Platform 7) Intelligent batch generation ... contour smoothing 9) Single drag-and-drop operations to ...
... 12 amino acid synthetic peptide whose sequence is derived from ... (amino to carboxy terminus): C - S(338) - K ... - V - A - P - A(348). ... with the polyclonal antibody that reacts with this product and ...
Biology Products: